Asset Details
Do you wish to reserve the book?
La terapia CAR-T nel paziente anziano con linfoma B diffuso a grandi cellule ricaduto/refrattario. Caso clinico dell’Ospedale Policlinico San Martino di Genova
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
La terapia CAR-T nel paziente anziano con linfoma B diffuso a grandi cellule ricaduto/refrattario. Caso clinico dell’Ospedale Policlinico San Martino di Genova
Do you wish to request the book?
La terapia CAR-T nel paziente anziano con linfoma B diffuso a grandi cellule ricaduto/refrattario. Caso clinico dell’Ospedale Policlinico San Martino di Genova
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
La terapia CAR-T nel paziente anziano con linfoma B diffuso a grandi cellule ricaduto/refrattario. Caso clinico dell’Ospedale Policlinico San Martino di Genova
2025
Overview
CAR-T therapy (chimeric antigen receptor T-cell) has revolutionized the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) that have relapsed or are refractory to conventional chemotherapies. In particular, patients who have relapsed or are refractory to two lines of therapy are patients who have a poor prognosis. The advent of CAR-T immunotherapy is an innovative approach with which we can give hope of recovery even in the case of refractory disease, even for patients who are not candidates for high-dose therapies, for example due to age. Here we present a clinical case of a 74-year-old patient at second relapse, refractory to two lines of chemotherapy and subjected to third-line CAR-T with axicabtagene ciloleucel, after a good response to bridge therapy with rituximab polatuzumab and bendamustine (RPB). Complete remission of the disease still persists eleven months after treatment. Tolerance to CAR-T was excellent, with grade 1 cytokine release syndrome (CRS), no neurological complications (ICANS-immune effector cell-associated neurotoxicity syndrome) and no infectious complications. Severe hypogammaglobulinemia persists eleven months after CAR-T reinfusion, for which he still performs immunoglobulin replenishment for prophylactic purposes.
Publisher
Pensiero Scientifico Editore
Subject
We currently cannot retrieve any items related to this title. Kindly check back at a later time.